[go: up one dir, main page]

BR9814080A - Uso de compostos para atividade anti-prurìtica - Google Patents

Uso de compostos para atividade anti-prurìtica

Info

Publication number
BR9814080A
BR9814080A BR9814080-9A BR9814080A BR9814080A BR 9814080 A BR9814080 A BR 9814080A BR 9814080 A BR9814080 A BR 9814080A BR 9814080 A BR9814080 A BR 9814080A
Authority
BR
Brazil
Prior art keywords
compounds
pruritic activity
activity
pruritic
pruritically
Prior art date
Application number
BR9814080-9A
Other languages
English (en)
Inventor
Don E Griswold
Siegfried Benjamin Christensen
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of BR9814080A publication Critical patent/BR9814080A/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52Purines, e.g. adenine
    • A61K31/522Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

"USO DE COMPOSTOS PARA ATIVIDADE ANTI-PRURìTICA" A presente invenção refere-se a derivados de xantinas 8-substituídas que são usados na profilaxia ou terapida de doenças ou distúrbios que têm um componente prurítico.
BR9814080-9A 1997-10-17 1998-10-16 Uso de compostos para atividade anti-prurìtica BR9814080A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6374697P 1997-10-17 1997-10-17
PCT/US1998/021886 WO1999020280A1 (en) 1997-10-17 1998-10-16 Novel use of compounds for anti-pruritic activity

Publications (1)

Publication Number Publication Date
BR9814080A true BR9814080A (pt) 2000-09-26

Family

ID=22051225

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9814080-9A BR9814080A (pt) 1997-10-17 1998-10-16 Uso de compostos para atividade anti-prurìtica

Country Status (18)

Country Link
EP (1) EP1030666A4 (pt)
JP (1) JP2001520196A (pt)
KR (1) KR20010031149A (pt)
CN (1) CN1306426A (pt)
AR (1) AR015966A1 (pt)
AU (1) AU740875B2 (pt)
BR (1) BR9814080A (pt)
CA (1) CA2306985A1 (pt)
CO (1) CO4810374A1 (pt)
CZ (1) CZ20001376A3 (pt)
HU (1) HUP0003792A3 (pt)
IL (1) IL135581A0 (pt)
NO (1) NO20001847D0 (pt)
NZ (1) NZ503551A (pt)
PL (1) PL341062A1 (pt)
TR (1) TR200001040T2 (pt)
WO (1) WO1999020280A1 (pt)
ZA (1) ZA989450B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20031902A3 (cs) 2001-01-31 2004-07-14 Pfizer Products Inc. Etherové deriváty užitečné jako inhibitory isozymů PDE4
OA12542A (en) 2001-01-31 2006-06-05 Pfizer Prod Inc Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of PDE4isozymes.
US7250518B2 (en) 2001-01-31 2007-07-31 Pfizer Inc. Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
NZ526453A (en) 2001-01-31 2005-01-28 Pfizer Prod Inc Nicotinamide biaryl derivatives useful as inhibitors of PDE4 isozymes
US20030175314A1 (en) * 2001-11-19 2003-09-18 Didriksen Erik Johannes Pharmaceutical composition for dermal application
TW200503709A (en) * 2003-07-17 2005-02-01 Santen Pharmaceutical Co Ltd Itching treating agent containing piperidine derivative as active ingredient
WO2005053672A1 (ja) * 2003-12-04 2005-06-16 Santen Pharmaceutical Co., Ltd. シロミラストまたはその塩を有効成分とする掻痒治療剤
JP2005187458A (ja) * 2003-12-04 2005-07-14 Santen Pharmaceut Co Ltd シロミラストまたはその塩を有効成分とする掻痒治療剤
WO2005077950A2 (en) * 2004-02-14 2005-08-25 Smithkline Beecham Corporation Medicaments with hm74a receptor activity
JP2008137892A (ja) * 2005-03-04 2008-06-19 Eisai Co Ltd 止痒剤
EA200800564A1 (ru) 2005-08-10 2008-08-29 Смитклайн Бичам Корпорейшн Производные ксантина как селективные агонисты нм74а
EP1992622B1 (en) * 2006-02-21 2011-07-27 Eisai R&D Management Co., Ltd. 4-(3-benzoylaminophenyl)-6,7-dimethoxy-2- methylaminoquinazoline derivative
TWI404709B (zh) * 2006-02-21 2013-08-11 Eisai R&D Man Co Ltd 4- (3-benzamidophenyl) -6,7-dimethoxy-2-methylamine quinazoline derivatives
WO2008099887A1 (ja) 2007-02-16 2008-08-21 Eisai R & D Management Co., Ltd. メチル n-[3-(6,7-ジメトキシ-2-メチルアミノキナゾリン-4-イル)フェニル]テレフタラミックアシッドの結晶、非晶質体または塩
AU2008290000B2 (en) 2007-08-17 2012-05-10 Eisai R & D Management Co., Ltd. Method for producing quinazoline derivative
WO2009025239A1 (ja) 2007-08-17 2009-02-26 Eisai R & D Management Co., Ltd. 新規外用剤
EP2727594B1 (en) * 2011-06-28 2017-12-20 Mitsubishi Tanabe Pharma Corporation Naphtalene compounds to treat itch
SMT202100359T1 (it) 2015-01-30 2021-07-12 Shanton Pharma Pte Ltd Prevenzione o trattamento della malattia dell'acido urico o della gotta

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU649091B2 (en) * 1990-12-21 1994-05-12 Beecham Group Plc Xanthine derivatives
ES2184077T3 (es) * 1996-03-26 2003-04-01 Altana Pharma Ag Nuevas fenantridinas sustituidas en la posicion 6.
EP0912568B1 (en) * 1996-05-15 2002-11-20 ALTANA Pharma AG imidazopyridines
WO1998040382A1 (en) * 1997-03-07 1998-09-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel tetrazoles
WO1998041232A2 (en) * 1997-03-18 1998-09-24 Basf Aktiengesellschaft Compositions for modulating responsiveness to corticosteroids
US6384047B1 (en) * 1997-06-03 2002-05-07 Byk Gulden Lomberg Chemische Fabrik Gmbh Benzonaphthyridine

Also Published As

Publication number Publication date
AR015966A1 (es) 2001-05-30
PL341062A1 (en) 2001-03-26
NO20001847L (no) 2000-04-10
EP1030666A1 (en) 2000-08-30
KR20010031149A (ko) 2001-04-16
CO4810374A1 (es) 1999-06-30
TR200001040T2 (tr) 2001-01-22
WO1999020280A1 (en) 1999-04-29
HUP0003792A3 (en) 2001-12-28
CZ20001376A3 (cs) 2002-06-12
CN1306426A (zh) 2001-08-01
JP2001520196A (ja) 2001-10-30
IL135581A0 (en) 2001-05-20
EP1030666A4 (en) 2002-10-16
HUP0003792A2 (hu) 2001-10-28
CA2306985A1 (en) 1999-04-29
AU740875B2 (en) 2001-11-15
ZA989450B (en) 1999-04-19
NO20001847D0 (no) 2000-04-10
AU1093899A (en) 1999-05-10
NZ503551A (en) 2002-05-31

Similar Documents

Publication Publication Date Title
BR9814080A (pt) Uso de compostos para atividade anti-prurìtica
BR9911488A (pt) Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou de profilaxia de doenças inflamatórias, e para a preparação de um composto
BR9714082A (pt) Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto.
BR9911482A (pt) Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto
BR9507917A (pt) Reagente para preparar um agente radiofarmacêutico agente formador de imagem processo para preparar o mesmo kit para preparar uma preparação farmacêutica uso do reagente agente radioterapêutico composição e agente radiofarmacêutico
ES2052629T3 (es) Pirazolo(3,4-d)piridinas, procedimiento para su preparacion y utilizacion como medicamentos.
BR9907270A (pt) Composto, composição farmacêutica, uso de um composto, e, processos para tratamento ou profilaxia de doenças inflamatórias, por exemplo, asma ou copd, e para a preparação de um composto
BR0113146A (pt) Derivados de prolina e uso destes como drogas
EP0105635A3 (en) Nonirritating aqueous ophthalmic compositions comfort formulation for ocular therepeutic agents
BR9408407A (pt) Uso de inibidores pla2 como tratamento para doença de alzheimer
MX9709874A (es) N-(INDOL-2-CARBONIL) beta-ALANILAMIDAS SUSTITUIDAS Y DERIVADOS COMO INHIBIDORES DE GLUCOGENO FOSFORILASA, USO DE LOS MISMOS Y COMPOSICIONES QUE LOS CONTIENEN.
ES2138622T3 (es) Derivados de mercaptoacetilamido piridazo(1,2-a)(1,2)diazepina utilizados como inhibidores de encefalinasa y eca.
SV1999000147A (es) Derivados de 4, 4-biarilpiperidina ref. pc10083/82759/bb
BR9812944A (pt) Inibidores bicìclicos da cinase
DK0628044T3 (da) Terapeutiske nucleosider
NO965516L (no) Sterolderivater anvendt til regulering av meiose
BR0211863A (pt) 1-alquil ou 1-cicloalquiltriazolo[4,3a]quinazolin-5-onas como inibidores da fosfodiesterase
DE69404116D1 (de) Mit Zucker überzogene pharmazeutische Dosierungseinheit
MX9704037A (es) 1,1-dioxidos de 1,2,5-tiadiazolidin-3-ona 2-substituida y composiciones y metodo de uso de los mismos.
ES2043665T3 (es) 6,11-dihidro-11-(4-piperidiliden)-5h-benzo-(5,6)-ciclohepta-(1,2-b)-piridinas y composiciones y metodos de uso.
AU623805B2 (en) New use of anti-progestomimetic compounds
DK102892D0 (da) Purin-derivater, farmaceutisk praeparat omfattende forbindelserne samt forbindelser til brug som mellemprodukter
MX9704034A (es) Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso.
MX9303392A (es) Derivados de imidazo benzoxazin-1-ona substituidos y proceso para su preparacion.
BR9811631A (pt) Derivado de ácido carboxìlico e uso do mesmo

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A,7A,8A E 9A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1910 DE 14/08/2007.